Vivaglobin Approved - ZLB Behring - Treatment for Primary Immunodeficiencies
Vivaglobin is a subcutaneous immunoglobulin (Ig) replacement therapy for treating patients with primary immunodeficiencies (PI).Posted: January 2006
Vivaglobin (immune globulin subcutaneous (human)) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
